seekingalpha.comNov 11$HALO

Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ)

Halozyme Therapeutics (HALO) shares fell Wednesday after Morgan Stanley downgraded the stock to Equal Weight from Overweight, citing valuation concerns following Q3 2026 results. Analyst Sean Laaman raised the price target to $45 from $40.

Original reporting

seekingalpha.com

Published Nov 11, 2026, 5:09 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 11, 2026, 5:15 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ) — source image — Source · seekingalpha.com

Decision brief

The 30-second read

$HALOBearishHigh

Why it matters

The downgrade reflects concerns about valuation despite recent results, likely prompting short-term price weakness.

Market read

Analyst downgrade may trigger sell pressure in Halozyme and influence sector sentiment.

What to watch

Potential upcoming clinical data could offset valuation concerns.

Relevance 7/10Novelty 7/10Timing: today

Background

Halozyme develops Enhanze drug delivery technology; its Q3 2026 results were recently released.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HALOBearishHigh confidence

Context

Morgan Stanley downgraded Halozyme Therapeutics to Equal Weight from Overweight following its Q3 2026 results.

Expected impact

likely downside as investors price in the lower rating

Evidence & confidence

Analyst downgrade is a fresh, material event that often triggers short-term sell pressure.

Market effects

Sector

May weigh on biotech and drug delivery sector sentiment.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Some investors may see the downgrade as an overreaction and a buying opportunity.

Key entities

Analyst
Morgan Stanley
Equity research firm issuing the downgrade.
Company
Halozyme Therapeutics
Biotech firm developing Enhanze technology.

Read at source ← All news

$HALOMed

Halozyme downgraded at Morgan Stanley on valuation

Morgan Stanley downgraded Halozyme Therapeutics (HALO) to Equal Weight, citing valuation concerns after its Q3 2026 results. Analyst Sean Laaman raised the price target to $109. HALO shares are up 53% YTD, outperforming the Nasdaq Biotechnology Index. The company faces royalty-rate step-downs, including for Johnson & Johnson's (JNJ) Darzalex SC.

tradingview.comNov 11

$HALOMedAI 8/10

Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance

Halozyme Therapeutics (HALO) shares dropped 4.28% to $117.69 on November 6, despite reporting a 39% revenue increase to $493 million and slightly higher 2026 guidance. Royalty revenue rose 44% to $341 million, and GAAP EPS increased to $2.01. The company's 2026 revenue guidance was raised to $1.860B-$1.925B, with non-GAAP EPS now $8.75-$9.05.

finance.yahoo.comNov 6

$HALOHighAI 8/10

Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

Halozyme Therapeutics reported Q3 2026 adjusted earnings of $2.39 per share, beating estimates. Revenue rose 39.2% YoY to $493M, driven by product sales and royalties. Despite the beat, shares fell 6% after-hours. The company raised 2026 guidance, projecting revenue of $1.86B-$1.93B and adjusted EBITDA of $1.24B-$1.29B.

tradingview.comNov 6

$JNJHigh

J&J's RYBREVANT FASPRO Approved By FDA For Advanced Head And Neck Cancer; Stock Down

FDA approved J&J's (JNJ) RYBREVANT FASPRO, co-formulated with HALO's ENHANZE, for advanced head and neck cancer. The treatment targets EGFR and MET proteins. HALO's stock is down 12.61% to $107.46.

rttnews.comNov 6

$JNJHigh

FDA approves Rybrevant Faspro for head and neck cancer

FDA granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO for head and neck cancer treatment. The drug, co-formulated with Halozyme's ENHANZE technology, targets specific receptors. Halozyme (HALO) licenses its technology to multiple pharmaceutical companies. The therapy was previously approved for lung cancer.

investing.comNov 6

$HALOHigh

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

Halozyme (HALO) announced FDA approval for RYBREVANT FASPRO, co-formulated with its ENHANZE technology, for treating advanced head and neck cancer. The approval expands the drug's use beyond lung cancer, targeting a high unmet need. Halozyme's CEO highlighted the technology's role in improving patient treatment options. Johnson & Johnson, which markets the drug, issued a separate press release.

prnewswire.comNov 6